Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Should You Sell?

Sysmex Corporation ADR (OTCMKTS:SSMXY) shares gapped down before the market opened on Monday . The stock had previously closed at $8.72, but opened at $8.36. Sysmex shares last traded at $8.37, with a volume of 3,981 shares traded.

Analyst Ratings Changes

Separately, Citigroup downgraded shares of Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Sysmex has a consensus rating of “Hold”.

Sysmex Price Performance

The company’s fifty day moving average price is $8.82 and its 200 day moving average price is $9.59. The company has a market capitalization of $5.29 billion, a P/E ratio of 17.52 and a beta of 1.10. The company has a quick ratio of 2.44, a current ratio of 3.33 and a debt-to-equity ratio of 0.12.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Thursday, February 12th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. Sysmex had a net margin of 8.86% and a return on equity of 9.27%. The company had revenue of $837.32 million for the quarter, compared to analysts’ expectations of $819.99 million. As a group, sell-side analysts forecast that Sysmex Corporation ADR will post 0.44 EPS for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.